There are new features regarding two of the available RBC kits (Fluogene and ReadyGene) that will be launched on August 2019.
- RBC-FluoGene vERYfy eXtend: A new primer-probe mix for detection of RHD*01W.59 (D weak type 59) will be incorporated in the test system.
- RBC-Ready Gene Rare ID: New primer mixes for detection of LW*A und LW*B will be incorporated. The number of reactions keeps the same..
Analyze the oral microbiome from saliva samples for subsequent microbial studies, key indicators of health.
Optimize the blood group genotyping and the compatibility in your patient's transfusions with the NEW KITS for specific blocking of high frequency antigens and neutralizing the interference by Daratumumab respectively.
Solution for the clinical diagnosis of myeloid disorders, by studying 30 genes by NGS.
Whole-gene amplification of MICA and MICB by Next-Generation Sequencing. RUO
Study of 42 genes associated, but not limited, to lung cancer, colorectal cancer, melanoma and glioma, with very high coverage.
Minimized risk of pipetting errors. For automated workflows (Illumina platforms)
New RBC-FluoGene vERYfy eXtend. Combining RHD, RHCE, KEL, JK, FY, MNS, DO, LU, YT, DI, VEL, CO and KN (including the complete
Rhesus D typing)
Treatment with Daratumumab in patients with multiple myeloma may interfere with blood compatibility tests.
Analysis of the immune response to cytomegalovirus, now with increased user convenience and a support software for an an easy and fast evaluation.
The Hereditary Cancer Solution (HCS) is a molecular diagnostic application that bundles the analytical power of Sophia with a capture-based target enrichment kit and full access to SOPHiA DDM® platform.
Diagnosis of the most frequent mutations associated with venous thrombosis: FII G20210A, FV G1691A and MTHFR C677T.
Infections of the respiratory tracts, gastroenteritis, viral meningitis, sexually transmitted diseases, HPV, fungal infections...
Pathofinder kits Read more
CE-IVD reagents for the detection of somatic mutations by Liquid Biopsy. Also available for FFPE.
Diagnostic of Fragile X Syndrome and other related disorders (such as FXPOI or FXTAS)
Launch of a new kit which is used for the prognosis of patients with Chronic Lymphocytic leukemia (CLL) by RT-PCR technology.
Renewed kit for the detection of the number of repeats of the CAG triplet in the IT15 gene (HTT) by fluorescent fragment analysis.
These blood bags allows preservation and sterile administration of blood components, moreover it includes a range of access points so that you can ensure you can process your products as you needed.
The HLA Typing Assay that provides comprehensive coverage of up to 11 HLA using NGS (Next Generation Sequencing). Now available as Research Use Only (RUO) and CE Marked for IVD use.
Thanks to its stabilizing solution, GeneFiX™ Saliva devices collect the saliva sample and stabilize the DNA for at least 36 months at room temperature.
New NimaPOP-4, NimaPOP-6 and NimaPOP-7 separation matrices compatible with ALL ABI Genetic Analyzers.
CE-IVD certificate now includes the NGSgo® workflow compatible with Illumina and AlleleSEQR® HLA CombiKits.
Very well used and popular antibodies used in Neuropathology research. For Human, Mouse and Rat samples.
Targeted next-generation sequencing (NGS) of specific genetic diseases or conditions.
Simultaneous detection of human 7 Familial Mediterranean Fever gene mutations
Base your reporting classification on In Vitro Diagnostics in accordance with the prevailing directives in Europe.
Discover also the wide range of BD Vacutainer Specialist Blood Collection Tubes for molecular biology testing.